Definium Therapeutics, Inc.
DFTX
$22.01
$0.854.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.94% | 25.96% | 17.41% | -3.00% | -16.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.81% | 60.04% | 61.43% | 44.02% | 19.60% |
| Operating Income | -69.81% | -60.04% | -61.43% | -44.02% | -19.60% |
| Income Before Tax | -206.01% | -69.12% | -71.88% | -12.23% | 38.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -206.01% | -69.12% | -71.88% | -12.23% | 38.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -206.01% | -69.12% | -71.88% | -12.23% | 38.06% |
| EBIT | -69.81% | -60.04% | -61.43% | -44.02% | -19.60% |
| EBITDA | -17.80% | -60.83% | -113.14% | -182.44% | -425.28% |
| EPS Basic | -163.60% | -13.85% | 0.72% | 39.67% | 67.80% |
| Normalized Basic EPS | -154.08% | -11.65% | 2.47% | 40.60% | 66.60% |
| EPS Diluted | -92.68% | -2.23% | 9.66% | 37.01% | 56.07% |
| Normalized Diluted EPS | -158.46% | -11.94% | 2.27% | 40.96% | 67.16% |
| Average Basic Shares Outstanding | 19.51% | 26.88% | 43.00% | 66.35% | 91.61% |
| Average Diluted Shares Outstanding | 16.68% | 25.05% | 40.48% | 65.72% | 96.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |